- Home
- GF vs PBYI Comparison
GF vs PBYI Comparison
Compare GF & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GF
- PBYI
- Stock Information
- Founded
- GF 1990
- PBYI 2010
- Country
- GF Germany
- PBYI United States
- Employees
- GF N/A
- PBYI N/A
- Industry
- GF Investment Managers
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- GF Finance
- PBYI Health Care
- Exchange
- GF Nasdaq
- PBYI Nasdaq
- Market Cap
- GF 167.2M
- PBYI 147.8M
- IPO Year
- GF N/A
- PBYI N/A
- Fundamental
- Price
- GF $9.34
- PBYI $2.87
- Analyst Decision
- GF
- PBYI Strong Buy
- Analyst Count
- GF 0
- PBYI 1
- Target Price
- GF N/A
- PBYI $7.00
- AVG Volume (30 Days)
- GF 28.1K
- PBYI 360.5K
- Earning Date
- GF 01-01-0001
- PBYI 05-01-2025
- Dividend Yield
- GF 0.82%
- PBYI N/A
- EPS Growth
- GF N/A
- PBYI 37.78
- EPS
- GF N/A
- PBYI 0.62
- Revenue
- GF N/A
- PBYI $230,468,000.00
- Revenue This Year
- GF N/A
- PBYI N/A
- Revenue Next Year
- GF N/A
- PBYI N/A
- P/E Ratio
- GF N/A
- PBYI $4.70
- Revenue Growth
- GF N/A
- PBYI N/A
- 52 Week Low
- GF $7.38
- PBYI $2.23
- 52 Week High
- GF $9.41
- PBYI $6.06
- Technical
- Relative Strength Index (RSI)
- GF 38.76
- PBYI 36.75
- Support Level
- GF $9.71
- PBYI $3.14
- Resistance Level
- GF $9.86
- PBYI $3.18
- Average True Range (ATR)
- GF 0.13
- PBYI 0.18
- MACD
- GF -0.15
- PBYI -0.07
- Stochastic Oscillator
- GF 0.00
- PBYI 6.62
About GF New Germany Fund Inc. (The)
NEW GERMANY FUND INC is a non-diversified, closed-end management investment company. As the investment objective, the fund seeks long-term capital appreciation through investment in middle-market German equities. The fund's portfolio of investment includes investments in different sectors such as the industrials, information technology, material, consumer discretionary, Communication Services, Financials, Consumer Staples, Real Estate, Utilities, Healthcare, Energy, and others. Its portfolio is geographically diversified across the Netherlands, Germany, and Luxembourg.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.